Aquestive Therapeutics (AQST) Gains from Investment Securities (2017 - 2018)

Aquestive Therapeutics' (AQST) quarterly Gains from Investment Securities came in at $4.1 million in Q3 2018, up 121.41% quarter-over-quarter from $1.9 million in Q2 2018.

Aquestive Therapeutics (AQST) Gains from Investment Securities (2017 - 2018) Analysis & Trends

Aquestive Therapeutics' Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $4.1 million for Q3 2018.

  • On a quarterly basis, Gains from Investment Securities changed N/A year-over-year to $4.1 million in Q3 2018; TTM through Jun 2019 was $4.1 million, a 108.3% increase from a year earlier, with the FY2018 full-year figure at $5.3 million, up 369.99% from the prior year.
  • Gains from Investment Securities grew to $4.1 million in Q3 2018 per AQST's latest filing, from $1.9 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $4.1 million in Q3 2018 and bottomed at -$697000.0 in Q1 2018.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 89.28 Bn 87.42 Bn -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn
6 RedHill Biopharma 22.11 Bn 22.11 Bn -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn
10 Aquestive Therapeutics 456.72 Mn 456.72 Mn 13.47 Mn

Historic Data

Download Data
DateValue
Sep 30, 2018 4.12 Mn
Sep 30, 2018 4.12 Mn
Jun 30, 2018 1.86 Mn
Jun 30, 2018 1.86 Mn
Mar 31, 2018 -697,000.00
Mar 31, 2018 -697,000.00
Dec 31, 2017 814,000.00
Dec 31, 2017 814,000.00
Jun 30, 2017 -111,000.00
Jun 30, 2017 -111,000.00